These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients. Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941 [TBL] [Abstract][Full Text] [Related]
3. Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure. Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KAMI; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma AJ; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG J Am Soc Nephrol; 2018 Sep; 29(9):2279-2285. PubMed ID: 30049681 [No Abstract] [Full Text] [Related]
4. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study. Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765 [TBL] [Abstract][Full Text] [Related]
5. Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies. Kim JJ; Shaw O; Martin C; Michaelides G; Balasubramaniam R; Sebire NJ; Mamode N; Dorling A; Vaughan R; Marks SD Pediatr Nephrol; 2018 Jan; 33(1):167-174. PubMed ID: 28918487 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study. Eskandary F; Bond G; Kozakowski N; Regele H; Marinova L; Wahrmann M; Kikić Ž; Haslacher H; Rasoul-Rockenschaub S; Kaltenecker CC; König F; Hidalgo LG; Oberbauer R; Halloran PF; Böhmig GA Transplantation; 2017 Mar; 101(3):631-641. PubMed ID: 27120452 [TBL] [Abstract][Full Text] [Related]
8. Does a Useful Test Exist to Properly Evaluate the Pathogenicity of Donor-specific Antibodies? Lessons From a Comprehensive Analysis in a Well-studied Single-center Kidney Transplant Cohort. Gautier Vargas G; Olagne J; Parissiadis A; Joly M; Cognard N; Perrin P; Froelich N; Guntz P; Gachet C; Moulin B; Caillard S Transplantation; 2020 Oct; 104(10):2148-2157. PubMed ID: 31895344 [TBL] [Abstract][Full Text] [Related]
10. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients. Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780 [TBL] [Abstract][Full Text] [Related]
11. Computer-assisted topological analysis of renal allograft inflammation adds to risk evaluation at diagnosis of humoral rejection. Sicard A; Meas-Yedid V; Rabeyrin M; Koenig A; Ducreux S; Dijoud F; Hervieu V; Badet L; Morelon E; Olivo-Marin JC; Dubois V; Thaunat O Kidney Int; 2017 Jul; 92(1):214-226. PubMed ID: 28318622 [TBL] [Abstract][Full Text] [Related]
12. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection. Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705 [TBL] [Abstract][Full Text] [Related]
13. Donor-specific HLA antibody-mediated complement activation is a significant indicator of antibody-mediated rejection and poor long-term graft outcome during lung transplantation: a single center cohort study. Roux A; Thomas KA; Sage E; Suberbielle-Boissel C; Beaumont-Azuar L; Parquin F; Le Guen M; Harre N; Hamid AM; Reed EF Transpl Int; 2018 Jul; 31(7):761-772. PubMed ID: 29537702 [TBL] [Abstract][Full Text] [Related]
14. C3d-binding Donor-specific HLA Antibody Is Associated With a High Risk of Antibody-mediated Rejection and Graft Loss in Stable Kidney Transplant Recipients: A Single-center Cohort Study. Lee DR; Kim BC; Kim JP; Kim IG; Jeon MY Transplant Proc; 2018 Dec; 50(10):3452-3459. PubMed ID: 30503524 [TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of C3d Assay in Kidney Transplant Recipients With Donor-Specific Anti-Human Leukocyte Antigen Antibodies. Paek JH; Kwon J; Lim J; Kim Y; Park WY; Jin K; Han S Transplant Proc; 2022 Mar; 54(2):341-345. PubMed ID: 35033370 [TBL] [Abstract][Full Text] [Related]
16. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation. Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025 [TBL] [Abstract][Full Text] [Related]
17. Detection of Complement-binding Donor-specific Antibodies, Not IgG-antibody Strength Nor C4d Status, at Antibody-mediated Rejection Diagnosis Is an Independent Predictor of Kidney Graft Failure. Malheiro J; Santos S; Tafulo S; Dias L; Martins S; Fonseca I; Almeida M; Pedroso S; Beirão I; Castro-Henriques A; Cabrita A Transplantation; 2018 Nov; 102(11):1943-1954. PubMed ID: 29757900 [TBL] [Abstract][Full Text] [Related]
18. Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d⁺ Antibody-Mediated Rejection in Kidney Transplant Recipients. Tatapudi VS; Kopchaliiska D; da Gente GJ; Buenaventura OF; Singh M; Laszik Z; Adey DB; Rajalingam R Ann Transplant; 2021 Dec; 26():e934175. PubMed ID: 34848674 [TBL] [Abstract][Full Text] [Related]
19. Antibody-mediated rejection after liver transplantation-relevance of C1q and C3d-binding antibodies. Kovandova B; Slavcev A; Sekerkova Z; Honsova E; Trunecka P HLA; 2018 Dec; 92 Suppl 2():34-37. PubMed ID: 30054978 [TBL] [Abstract][Full Text] [Related]
20. C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study. Moktefi A; Parisot J; Desvaux D; Canoui-Poitrine F; Brocheriou I; Peltier J; Audard V; Kofman T; Suberbielle C; Lang P; Rondeau E; Grimbert P; Matignon M Transpl Int; 2017 Mar; 30(3):277-287. PubMed ID: 27992962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]